IL-2 peptide derivatives, and uses thereof for the diagnosis and treatment of an autoimmune disease
An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-IL2 response, peptides specifically recognized by anti-IL2 antibodies or IL-2-specific T cells of T1D, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.
1. A peptide specifically recognized by anti-IL2 antibodies or IL-2-specific T cells of Type 1 diabetes (T1D), systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and autoimmune polymyositis patients, wherein said peptide is derived from IL-2 and consists of amino acid sequence:
(SEQ ID No 1)
LTRMLTFKFYMPKKA,
or
(SEQ ID No 2)
EFLNRWITFSQSIIS.
2. A method of therapeutic treatment of a disease of the human or animal body, comprising a step of administering a peptide according to claim 1 to a subject in need thereof, wherein the disease of the human or animal body is selected from the group consisting of type 1 diabetes (T1D), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SJO) and autoimmune polymyositis (JO1).
3. The method according to claim 2 , wherein the disease of the human or animal body is selected from the group consisting of type 1 diabetes (T1D), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).
4. A pharmaceutical composition comprising as active ingredient a peptide according to claim 1 and a pharmaceutical excipient.